InMed Pharmaceuticals, Inc. Q4 FY2020 earnings call

• Therapeutic development: INM-755 Phase 1 trial advanced, second Phase 1 trial near enrollment completion; INM-088 for glaucoma in preclinical testing near formulation selection.
• Cannabinoid manufacturing: IntegraSyn platform developed, working on scale-up for GMP-batch production.
• General updates: Progress made despite COVID-19; clinical trial applications for INM-755 EB study delayed to Q1 2021; IntegraSyn GMP batch-ready delayed to Q1 2021; share consolidation completed; capital managed carefully with focus on R&D commitments.

InMed has therapeutic development programs and a cannabinoid manufacturing platform. The lead clinical program INM-755 advanced to the second Phase 1 clinical trial nearing enrollment completion. INM-088 for glaucoma is in preclinical testing near formulation selection. IntegraSyn, the cannabinoid manufacturing platform, is being scaled up for GMP-batch production. No specific revenue contribution percentages provided.

• Anticipate Phase 1 trial results from INM-755 in Q4 2020.
• Clinical trial applications for INM-755 EB study now expected in Q1 2021, delayed from previous guidance.
• IntegraSyn GMP batch-ready now expected by end of Q1 2021, delayed from end of calendar 2020.
• Cash runway extended to at least Q3 2021 with cash management efforts.

• COVID-19 related restrictions impacting trial timelines and enrollment schedules.
• Protracted financing process due to regulatory delays, currently in a U.S. regulatory quiet period limiting comment on financing status.

Q: Changed timing for CTA filings for the EB trial, when might enrollment start?

A: Filings in Q1 2021, enrollment likely early in Q2.

Q: Status of INM-088 formulation decision?

A: Still evaluating, considering cost and economics of in-house vs external options.

Q: Pluses of the IntegraSyn process?

A: Cost efficiency, ability to mass produce enzyme for efficient cannabinoid production, and use of existing purification processes.

Q: Timeline for NASDAQ listing?

A: Ongoing, in regulatory quiet period, unable to speculate on exact timing but working diligently to move forward.

Q: Important patents?

A: Biosynthesis/IntegraSyn related patents and glaucoma neuroprotection patent are important; ongoing patent filings with expected allowances in near future.

Q: Status of INM-755 second Phase 1 trial?

A: Completing enrollment this week, COVID delays but center in Leiden helped keep on track.

Q: Importance of cannabinoid pharmaceuticals summit?

A: Important for advancing the field, combating misinformation about cannabinoids, and supporting pharmaceutical research development.